Astellas Pharma Inc. recently announced a strategic agreement with Sangamo Therapeutics, Inc. aimed at advancing the delivery of genomic medicines for certain neurological disorders. The partnership grants Astellas an exclusive global license to employ Sangamo's cutting-edge neurotropic adeno-associated virus (AAV) capsid, known as STAC-BBB, for one specific target initially. Astellas retains the option to include up to four more targets, contingent upon paying additional fees. According to the agreement, Sangamo will receive an upfront payment of $20 million and may earn up to $1.3 billion in milestone payments, along with mid-to-high single digit royalties on potential net sales related to the five potential disease targets.
The material has been provided by InstaForex Company - www.instaforex.com
The material has been provided by InstaForex Company - www.instaforex.com